Dramatic response of metaplastic breast cancer to chemo-immunotherapy

Abstract Frequent overexpression of programmed death-ligand 1 has recently been demonstrated in metaplastic breast cancer, which is a rare breast cancer subtype with limited treatment options. This report describes the clinical course of a patient with metastatic metaplastic breast cancer who had a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Sylvia Adams
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f7d023da910243e7ba102aee3fa471ff
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f7d023da910243e7ba102aee3fa471ff
record_format	dspace
spelling	oai:doaj.org-article:f7d023da910243e7ba102aee3fa471ff2021-12-02T11:50:52ZDramatic response of metaplastic breast cancer to chemo-immunotherapy10.1038/s41523-017-0011-02374-4677https://doaj.org/article/f7d023da910243e7ba102aee3fa471ff2017-03-01T00:00:00Zhttps://doi.org/10.1038/s41523-017-0011-0https://doaj.org/toc/2374-4677Abstract Frequent overexpression of programmed death-ligand 1 has recently been demonstrated in metaplastic breast cancer, which is a rare breast cancer subtype with limited treatment options. This report describes the clinical course of a patient with metastatic metaplastic breast cancer who had a remarkable response to anti-programmed death-1 therapy with pembrolizumab in combination with nab-paclitaxel. Tissue correlates are presented including tumor-infiltrating lymphocytes and high-programmed death-ligand 1 expression in the tumor.Sylvia AdamsNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 3, Iss 1, Pp 1-4 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Sylvia Adams Dramatic response of metaplastic breast cancer to chemo-immunotherapy
description	Abstract Frequent overexpression of programmed death-ligand 1 has recently been demonstrated in metaplastic breast cancer, which is a rare breast cancer subtype with limited treatment options. This report describes the clinical course of a patient with metastatic metaplastic breast cancer who had a remarkable response to anti-programmed death-1 therapy with pembrolizumab in combination with nab-paclitaxel. Tissue correlates are presented including tumor-infiltrating lymphocytes and high-programmed death-ligand 1 expression in the tumor.
format	article
author	Sylvia Adams
author_facet	Sylvia Adams
author_sort	Sylvia Adams
title	Dramatic response of metaplastic breast cancer to chemo-immunotherapy
title_short	Dramatic response of metaplastic breast cancer to chemo-immunotherapy
title_full	Dramatic response of metaplastic breast cancer to chemo-immunotherapy
title_fullStr	Dramatic response of metaplastic breast cancer to chemo-immunotherapy
title_full_unstemmed	Dramatic response of metaplastic breast cancer to chemo-immunotherapy
title_sort	dramatic response of metaplastic breast cancer to chemo-immunotherapy
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/f7d023da910243e7ba102aee3fa471ff
work_keys_str_mv	AT sylviaadams dramaticresponseofmetaplasticbreastcancertochemoimmunotherapy
_version_	1718395201946386432

Dramatic response of metaplastic breast cancer to chemo-immunotherapy

Ejemplares similares